Advertisement

Topics

BMS, Compugen to evaluate Opdivo-COM701 combo in advanced solid tumors

05:51 EDT 12 Oct 2018 | Pharmaceutical Business Review

While Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, COM701 is an investigational anti-PVRIG antibody. Apart from the clinical trial collaboration, Bristol-Myers Squibb has agreed to make

The post BMS, Compugen to evaluate Opdivo-COM701 combo in advanced solid tumors appeared first on Pharma Business review.

Original Article: BMS, Compugen to evaluate Opdivo-COM701 combo in advanced solid tumors

NEXT ARTICLE

More From BioPortfolio on "BMS, Compugen to evaluate Opdivo-COM701 combo in advanced solid tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...